AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CRISPR Therapeutics AG Director's Dealing 2016

Oct 20, 2016

30936_dirs_2016-10-20_06b4878a-61c8-4c37-a0c8-ef96e8efd9a5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2016-10-18

Reporting Person: Woiwode Thomas (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-10-18	Stock Option (Right to Buy)	$14.00	A	30000	Acquired	2026-10-18	Common Shares (30000)	Direct

Footnotes

F1: This option was granted on October 18, 2016 with respect to 30,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments beginning October 31, 2016.